Alogliptin benzoate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314210

CAS#: 850649-62-6 (benzoate)

Description: Alogliptin benzoate is a DPP-4 inhibitor used for the treatment of Type 2 diabetes. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.


Chemical Structure

img
Alogliptin benzoate
CAS# 850649-62-6 (benzoate)

Theoretical Analysis

MedKoo Cat#: 314210
Name: Alogliptin benzoate
CAS#: 850649-62-6 (benzoate)
Chemical Formula: C25H27N5O4
Exact Mass:
Molecular Weight: 461.522
Elemental Analysis: C, 65.06; H, 5.90; N, 15.17; O, 13.87

Size Price Shipping out time Quantity
2g USD 190 Same Day
5g USD 350 Same Day
10g USD 550 Same Day
50g USD 1450 Same Day
100g USD 2250 Same Day
1kg USD 7250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-03. Prices are subject to change without notice.

Alogliptin benzoate, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 850649-61-5 (free base)    

Synonym: SYR322, SYR 322, SYR-322, Nesina, Kazano, Oseni, Alogliptin benzoate.

IUPAC/Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile benzoate

InChi Key: KEJICOXJTRHYAK-XFULWGLBSA-N

InChi Code: InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1

SMILES Code: O=C(O)C1=CC=CC=C1.N#CC2=CC=CC=C2CN(C(N3C)=O)C(N4C[C@H](N)CCC4)=CC3=O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 461.522 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther. 2013 Sep 17;7:989-1001. doi: 10.2147/DDDT.S37647. eCollection 2013. Review. PubMed PMID: 24068868; PubMed Central PMCID: PMC3782406.

2: Agrawal R, Bahare RS, Jain P, Dikshit SN, Ganguly S. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. Mini Rev Med Chem. 2012 Nov;12(13):1345-58. Review. PubMed PMID: 22512582.

3: Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar;13(4):553-63. doi: 10.1517/14656566.2012.656088. Epub 2012 Feb 1. Review. PubMed PMID: 22296609.

4: Ueki K. [A compounding agent of alogliptin and pioglitazone]. Nihon Rinsho. 2011 May;69(5):877-82. Review. Japanese. PubMed PMID: 21595275.

5: Tanabe A, Kaku K. [Alogliptin]. Nihon Rinsho. 2011 May;69(5):871-6. Review. Japanese. PubMed PMID: 21595274.

6: White JR. Alogliptin for the treatment of type 2 diabetes. Drugs Today (Barc). 2011 Feb;47(2):99-107. doi: 10.1358/dot.2011.47.2.1583163. Review. PubMed PMID: 21431099.

7: Takeuchi K, Fujita T, Hiroi S. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)]. Nihon Yakurigaku Zasshi. 2011 Jan;137(1):43-50. Review. Japanese. PubMed PMID: 21233588.

8: Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010 Oct 22;70(15):2051-72. doi: 10.2165/11205080-000000000-00000. Review. Erratum in: Drugs. 2010 Dec 24;70(18):2475. PubMed PMID: 20883057.



Additional Information

Related:
850649-62-6 (Alogliptin benzoate)
850649-61-5 (Alogliptin free base).